Blar i Institutt for klinisk og molekylær medisin på forfatter "Aakhus, Svend"
-
Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial
Kleveland, Ola; Kunszt, Gabor; Bratlie, Marte; Ueland, Thor; Broch, Kaspar; Holte, Espen; Michelsen, Annika; Bendz, Bjørn; Amundsen, Brage H.; Espevik, Terje; Aakhus, Svend; Damås, Jan Kristian; Aukrust, Pål; Wiseth, Rune; Gullestad, Lars (Journal article; Peer reviewed, 2016)Aims Interleukin-6 (IL-6) contributes to atherosclerotic plaque destabilization and is involved in myocardial injury during ischaemia–reperfusion. Interleukin-6 is therefore a potential therapeutic target in myocardial ... -
Increased complement factor B and Bb levels are associated with mortality in patients with severe aortic stenosis
Shahini, Negar; Ueland, Thor; Auensen, Andreas; Michelsen, Annika; Ludviksen, Judith K; Hussain, Amjad Iqbal; Pettersen, Kjell; Aakhus, Svend; Espeland, Torvald; Lunde, Ida Gjervold; Kirschfink, Michael; Nilsson, Per; Mollnes, Tom Eirik; Gullestad, Lars; Aukrust, Pål; Yndestad, Arne; Louwe, Maria Cornelia (Journal article; Peer reviewed, 2019)Inflammation is involved in initiation and progression of aortic stenosis (AS). However, the role of the complement system, a crucial component of innate immunity in AS, is unclear. We hypothesized that circulating levels ... -
Interleukin-6 receptor inhibition with tocilizumab induces a selective and substantial increase in plasma IP-10 and MIP-1β in non-ST-elevation myocardial infarction
Kleveland, Ola; Ueland, Thor; Kunszt, Gabor; Bratlie, Marte; Yndestad, Arne; Broch, Kaspar; Holte, Espen; Ryan, Liv; Amundsen, Brage H.; Bendz, Bjørn; Aakhus, Svend; Espevik, Terje; Halvorsen, Bente; Mollnes, Tom Eirik; Wiseth, Rune; Gullestad, Lars; Aukrust, Pål; Damås, Jan Kristian (Journal article; Peer reviewed, 2018)Aim To evaluate the effect of interleukin-6 inhibition with tocilizumab on the cytokine network in patients with acute non-ST-elevation myocardial infarction (NSTEMI). Methods 117 patients with acute NSTEMI were randomised ... -
Rationale for the ASSAIL-MI-trial: a randomised controlled trial designed to assess the effect of tocilizumab on myocardial salvage in patients with acute ST-elevation myocardial infarction (STEMI).
Anstensrud, Anne Kristine; Woxholt, Sindre; Sharma, Kapil Kishore; Broch, Kaspar; Bendz, Bjørn; Aakhus, Svend; Ueland, Thor; Amundsen, Brage H.; Damås, Jan Kristian; Hopp, Einar; Kleveland, Ola; STENSÆTH, KNUT HAAKON; Opdahl, Anders; Kløw, Nils-Einar; Seljeflot, Ingebjørg; Andersen, Geir Øystein; Wiseth, Rune; Aukrust, Pål; Gullestad, Lars (Journal article; Peer reviewed, 2019)Introduction Interleukin-6 (IL-6) may be involved in ischaemia-reperfusion injury and myocardial remodelling after myocardial infarction (MI). We have recently shown that IL-6 inhibition by tocilizumab attenuates systemic ...